A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol and cocaine.
A new case series links GLP-1 use to three different eye conditions, all of which can lead to blindness.
An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether someone has obesity, alongside other major changes.
The FDA has approved Eli Lilly's Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity.
Several recent studies have found a possible connection between semaglutide use and a rare condition that causes sudden vision loss.
A study of 14,000 WeightWatchers participants is the latest to suggest that Ozempic and similar obesity drugs could be adapted into treatments for substance use disorders.
A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.
New research estimates that expanded access to Ozempic and similar drugs could lead to 42,000 deaths prevented annually.
Research from earlier this week is the latest to suggest that semaglutide and other GLP-1 drugs can help treat people's addiction to both opioids and alcohol.
A new survey shows that most people would rather try dieting to lose weight than take the latest injectable drugs like Ozempic.
New research suggests GLP-1 medications can blunt people's cravings for potentially addictive substances like opioids.
Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect our body? And what's left to learn?
